aptaTargets

clinical-stage biopharmaceutical using aptamer technology for targeting acute indications.

(Lead-candidate) is a neuroprotective drug for acute ischemic stroke by targeting inflammation in the acute phase.

where inflammation causes significant damage, including ischemic stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis.